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Background: Pramipexole is a dopaminergic receptor agonist with high selectivity for the 
D2-receptor family. It is used in the treatment of neurological disorders such as Parkinson’s 
disease. It is effective to improve motor symtoms in this condition. It has however 
behavioural side effects related to impulsivity, such as pathologic gambling and excessive 
shopping. Animal studies using different models for impulsivity, such as the delay 
discounting task, have seen an increase in impulsive behaviour in rats treated with 
Pramipexole.  
OSU6162 is a dopaminergic stabilizer which has been shown to improve impulsive behaviour 
in rats.  
Aim: To investigate if rats treated with Pramipexole would show increased impulsive 
behaviour in the delay discounting task. And if so, whether this increase in impulsivity can be 
attenuated by OSU6162. 
Methods: 10 male Wistar rats were trained in the delay discounting task. When training was 
complete, they were given subcutaneous injections of Pramipexole (1 mg/kg and 0.1 mg/kg) 
20 minutes before starting the delay discounting task. 
Results: Treatment of Pramipexole resulted in drowsy behaviour and the data was not further 
analysed. Because of time limitations, the project was not continued beyond these 
experiments. 
Conclusion: While some other studies have seen an increase in impulsive behaviour in rats 
treated with Pramipexole, using the delay discounting task, this effect seems slightly elusive. 
Further tests with different doses of Pramipexole should be performed. The sedating effect of 




How to define impulsivity 
Impulsivity is a broad term that can encompass many different behaviors. Daruna&Barnes 
(1993) provides a definition that is also useful outside of academic research: 
“… impulsivity encompasses actions that appear poorly conceived, prematurely expressed, 
unduly risky or inappropriate to the situation and that often results in undesirable 
consequences.” (1) 
Others, such as Barratt (1994) have recognized that the term impulsivity seem to include a 
number of different dimensions, such as motor impulsivity (acting without thinking), and non-
planning impulsivity (lack of concern for the future). These are factors that are included in the 
Barratts impulsivity scale (BIS) (2). 
Impulsivity in psychiatric disorders 
Impulsivity, as defined above, seems to play a part in several psychiatric diseases.   
For personality disorders, such as borderline personality disorder, the diagnostic criteria 
include “impulsive and reckless behaviour”. For antisocial personality disorder, one of several 
diagnostic criteria that can be related to impulsivity is “reckless disregard for safety of self 
and others” (3). 
Other important diagnoses in this regard is ADHD (attention deficit/hyperactivity disorder) 
and impulse control disorders, including drug and alcohol abuse as well as pathologic 
gambling and kleptomania (3). 
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Biological background to impulsivity 
Both serotonergic and dopaminergic transmission has been seen to affect impulsive behavior 
in animal studies. Different receptor subtypes for these transmitters seem to affect impulsive 
behavior in different ways. For example, pre-clinical studies have shown opposite effect of 5-
HT2c-antagonism and 5-HT2a-antagonism in the same model of impulsivity (4). 
There also seem to be a paradox regarding the influence of dopamine on impulsivity where 
ADHD-medication that stimulates dopamine release improves symptoms but dopaminergic 
agonists and L-dopa used in the treatment of Parkinson can result in side effects such as 
pathologic gambling, increased libido and excessive shopping (4, 5). 
How to measure impulsivity 
Reflecting the above mentioned definition of impulsivity as having several aspects, the 
models for studying impulsivity is generally divided in a two main groups: models that study 
impulsive action (or so called motor impulsivity) and those that study impulsive choice (6). 
Impulsive action can be studied in models that require the subject to withhold a response. 
Common models used for the study of animals such as rat are Go/-no go and SSRT (stop 
signal reaction time). In the Go-/no-go for example, the rat can earn a reward by pressing a 
lever when the “go-signal” shows (which can be a stimuli-light) and when the “no-go signal” 
shows it must refrain from pressing the lever to earn the reward (7). 
Impulsive choice can be studied in models such as the delay discounting task (6). 
Delay discounting as a way of studying impulsivity in animals 
Delay discounting has been used extensively to study impulsive behaviour in both animals 
and humans (4). The general principle of the method is that the subject is given a choice 
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between two rewards, one of them is larger and delivered after a delay and the other is smaller 
and delivered immediately. Impulsive behavior is then defined as choosing the smaller (but 
immediate) reward more often (3). 
In practice this can be achieved in many ways, earlier methods, such as Thiébot (1985), did 
for example use a maze where the longer path led to the larger reward (8). Nowadays this is 
usually achieved by using levers and systems to automatically deliver the reward after a delay 
(3). 
A way to use the delay discount procedure is to stepwise increase the delay to the large 
reward. Introduced by Evenden (1996) this is a common method for studying rats. The result 
of this method is a delay-discount curve that sees the decreased choice of the larger reward as 
the delay increase (9). 
The list of drugs tested in rat using the delay discount task is quite extensive. Among the most 
studied is amphetamine which is usually seen to increase impulsive choice (that is, choice of 
the smaller reward) (3). 
Dopaminergic receptor agonists 
Pramipexole is a dopaminergic receptor agonist used in the treatment of neurological diseases 
such as Parkinson’s disease where it is used alone or in combination with L-dopa (10). It has 
high selectivity for dopamine D2-receptors and does not interfere much with serotonergic and 
adrenergic receptors (11). 
In Parkinson patients, Pramipexole improves control of motor symtoms. Side effects however 
includes behavioral problems such as impulse control disorders (12). 
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OSU6162 - a dopaminergic stabilizer 
OSU6162 was developed during the 1980's by researchers in Gothenburg (13). Among them 
Arvid Carlsson who in 2000 was awarded the Nobel price in Medicine or Physiology for the 
discovery of dopamine as a neurotransmitter in the CNS (14). 
OSU6162 is known as a dopamine stabilizer and has affinity for dopaminergic D2 and D3-
receptors where it seems to function as an antagonist(15). It also seems to have antagonistic 
effect on 5-HT1- and 5-HT2-receptors (16).  
The term "dopamine stabilizer" comes from the ability to stabilize behaviour related to 
dopaminergic functions. It has for example been shown to attenuate the hyperlocomotion 
induced by amphetamine in rats (17) as well as increase the locomotion in rats who has less 
baseline activity as a result of habituation (18). 
OSU6162 has also been tested in humans, as a potential treatment against alcohol dependence 
(19), fatigue induced by brain damage (20) and Huntingtons disease (21). 
A study by Fredriksson (2019) saw improved motor impulsivity in rats treated with 
OSU6162. It was suggested that the improved impulsive control can contribute to the ability 
of OSU6162 to attenuate alcohol-mediated behaviour (22). 
Aim 
The aim of this project is to investigate if rats treated with the dopaminergic agonist 
Pramipexole will show increased impulsive behaviour in the delay discounting task. And if 




Materials and methods 
Materials and equipment 
Training and testing were done using 10 operant conditioning chambers (see figure 1 and 2). 
The chambers were equipped with two retractable levers, left and right of a pellet dispenser. 
Above each lever was a stimulus light and on the opposite wall was a house light. 
4 infrared photodiodes register movement in the chamber and one photodiode registered 
movement in the pellet receptacle. 
The pellet dispenser delivered 45 mg sucrose pellets. 
The software controlling the chambers was written in-house by the author of this thesis.   
 
Figure 1. The operant conditioning chamber used for the delay discounting task. (A) two stimuli 
lights. (B) Left lever. (C) Right lever. (D) Pellet dispenser. (E) infrared photodiodes that detect 





Figure 2.The operant conditioning chamber. (F) The house light. 
 
Training in the operant conditioning boxes 
The protocol for the delay discount task was based on the one used by Mar & Robbins (2007) 
(23). 
Preparation 
Before start of training, the animals were handled by the researcher in order to accommodate 
them to human interaction. This was done by lifting up and gently petting the animals for 
around one minute. 
Each animal were weighed and marked using a permanent marker pen (each assigned a 
number 1-10) on the tail. 
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The animals were assigned one operant box each, so that they would use the same box 
throughout the entire project (that is, both training and experimental procedures). 
Fixed ratio 
The aim of the very first training in the operant chambers was to teach the animals to use the 
levers to gain sucrose pellets.This was done using a fixed ratio 1 schedule, that is, one lever 
press results in one pellet.  
This was done once daily and each session lasted 30 min. 
During the session, both levers were extended and so could be pressed but only one was 
active and pressing this resulted in a sugar pellet being delivered. 
The animals were counterbalanced for which lever were learned first, so half of the rats 
started with the left lever active and the other half started with the right lever active. 
The animals were regarded as having learned to use a lever when 30 lever presses, resulting in 
a sugar pellet each, were made during a session. It took between 9-25 sessions for all animals 
to learn this. 
When the animal had learned to use both levers it would, the next session, start training on the 
delay discounting task. 
Delay discounting task 
One session per day, 5-7 days/week was conducted. Each session consisted of 4 blocks with 
different delays (0 sec, 10, 20, 40), the blocks were in this order of increasing delay. In turn, 
each block consisted of 10 trials, 8 of which were free-choice trials when the animal could 
chose between the two levers. 2 of the trials were forced-choice, in which only one lever was 
extended and available to press. For a schematic representation of the task se figure 3. 
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Each trial lasted 100 seconds. When a trial started, the house light turned on and the levers 
were extended (only one lever if it was a forced choice trial). If no lever were pushed within 
10 seconds, the levers were again retracted and the house light turned off, this would be 
registered as an omission. The animal would then spend the rest of the trial in the dark until 
the next trial started. 
If the animal pushed one lever within the 10 second time limit it would result in a sugar pellet 
immediately being delivered via the pellet dispenser or it would have 3 pellets delivered after 
a delay depending on which lever was pushed. The delay would depend on which block the 
trial was in. 
So for example, if the rat chose the lever assigned as the “delay-lever” during the second 
block, 3 pellets would drop after a delay of 10 seconds. 
The aim of the training in the delay discount task was to achieve stable choice between 
sessions as well as an effect of delay on the choice. Ideally, the choice of the delay lever 
should be high in the first block, when the delay is 0 seconds. When this was achieved, 
experiments with pharmacological compounds could be started using the delay discounting 
task. 
After around 2 weeks of training, while the session to session choice of the delayed lever was 
stable, the animals chose the delayed lever only around 40% of the time in the first block and 




Figure 3. A schematic representation of the delay discounting task. In this example, each 
block consists of 2 forced choice trials and 3 free choice trials. 
Change of protocol for delay discounting 
In order to achieve a higher choice of the delayed lever in the first block as well as to see an 
effect on choice depending on delay, it was decided to make changes to the protocol.  
The reward for choosing the delayed-lever was increased to 4 sugar pellets and the stimuli 
light would signal the delay-time to make it more clear to the animal that pushing the lever 
would result in a reward being delivered.  
An additional moment was also added to the very start of the trial, where the animal now had 
to nose poke into the pellet receptacle for the levers to be extended. This was to ensure the 
animal would be centered between the two levers when they were extended.  
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The number of free choice trials in respective block was reduced from 8 to 6, while the 
number of forced-choice was kept at 2 per block. 
The length of each trial was also reduced, depending on the delay time, so that the entire 
session lasted for 30 minutes instead of 65 minutes. This would make it likely that the plasma 
levels of the pharmacological compounds to be tested would stay more even over the course 
of the test. 
Experimental procedures 
After 9 sessions of training on the delay discount task after a new protocol was adopted, the 
rats showed an effect of delay as well as a choice of the delayed lever at around 80% at the 
first block (0 seconds delay to large reward).They were thus ready for testing of the drug. 
The experiment was designed as a cross-over study. The 10 animals were randomized into 
two groups, 5 animals in each. For each dose of the drug tested, there were two test days. 
On testing day 1, one of the groups received injections with the drug and the other group 
received vehicle injection. 20 minutes after injection, the animals were placed in the boxes 
and the session started. 
On testing day 2, the treatment was reversed so that the group that received drug injection 
now received vehicle injection, and vice versa. 
Between the two test-days were 2 days of rest and 1 day of normal training without injections.  
Drugs 
Pramipexole was dissolved in saline (0.9%) and was given in subcutaneous injection, with an 
injection volume of 2 ml/kg. 




10 male, Wistar rats from Charles River, Germany. 3 months of age at arrival and around 6 
months of age at the start of the experimental procedures. 
Housed 2-3 per cage at a 12 hour light cycle (7 am – 7 pm).  
Food and water were available ad libitum. 
Ethics 
The ethical number for the animal research conducted in this project is 137-2015. The 
research was approved by the regional ethics committee in Gothenburg (Göteborgs 
djurförsöksetiska nämnd). 
Data analysis 
The primary variable analyzed were the choice of the delayed lever during free choice trials, 
as a percentage of the total lever presses during respective block.  
Other variables analyzed were movement in the box, head pokes during delay period, 
omissions and latency to press lever. 





Figure 4. Average choice of the delayed lever at the end of training in the delayed 
discounting task (n = 10). This was after 9 sessions using the new protocol. Error bars: +/- 2 
SE.  
 
Training was completed after 9 sessions in the delay discounting task. As can be seen in 
figure 4, there was considerable variation in choice of lever. A repeated measure, within 
subject ANOVA showed no significant effect of delay (F = 6.538, p = 0.136). 
Two doses of Pramipexole were tested, first 1 mg/kg and then 0.1 mg/kg. Unfortunately both 
doses resulted in the animals appearing somnolent and very few lever presses were registered. 
The animals that received treatment were mostly sleeping while in the box. Therefore the data 
was not further analyzed. 
Using the first dose of 1 mg/kg Pramipexole, only one animal completed all 4 blocks (in other 
words, it achieved the designated threshold of 3 lever presses per block), whereas all other 
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animals made no lever presses at all. 
In the vehicle group on the other hand, only one animal failed to complete all 4 trials. 
When administered the second dose of 0.1 mg/kg, more lever presses were made. However, 
the treated animals completed in total only 17 blocks out of a possible 40 (10 animals, 4 
blocks each).  
When given the vehicle solution the animals completed 33 out of 40 blocks. 
Discussion 
The aim of this project was to first asses if the dopaminergic agonist Pramipexole could have 
an effect on impulsive choice in the delay discounting task, and if so, if the dopamine 
stabilizer OSU6162 could attenuate this effect. 
One earlier study with rats treated with Pramipexole have seen an increase of impulsive 
behavior in the delay discounting task at doses ranging between 0.1-0.3 mg/kg, and a 
tendency towards impulsive behavior at 0.03 mg/kg (24). However the effect could be 
elusive, as Koffarnus (2011) did not see a significant effect at those doses (25). 
In one other study, using a different model of impulsivity, Pramipexole was shown to increase 
impulsivity at 0.3 mg/kg and 1 mg/kg (26). 
Due to time limitations only two doses of Pramipexole were tested during the project. 
Unfortunately, both doses resulted in such a large number of omissions, and the animals being 
visibly tired, that the results were not further analyzed. 
Earlier studies have seen a dose-dependent increase of omissions in the delay discounting task 
with doses ranging from 0.10 – 0.30 mg/kg (24) and other studies indicates that Pramipexole 
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has an effect on locomotion and sleep in rats (27).  
Doses between 0.1-0.3 mg/kg are generally used in behavioral models when studying 
Pramipexole (28). It seems strange therefore that 0.1 mg/kg, when tested in this experiment 
would make the animals so sleepy. This could be due to a too short wash out period after the 
larger dose or experimental errors when handling the drugs for example. It seems warranted 
to try doses in this range again. 
What took the most time during the project was the training of the animals in the delay 
discounting task. Because the response was not satisfactory using the first protocol a change 
of protocol was made, which meant that more time for training was needed. 
The change of protocol that was made was due to the low choice of the delayed-lever at 0 
seconds and little effect of the increasing delay on choice.  
This meant that there was little room for more “impulsive” choice to be seen, as the animals 
often choose the immediate reward at baseline. 
The addition of a cue light to signal the delay was added to the procedure in order to speed up 
the learning process and increase the choice of the delayed lever, as has been observed in an 
earlier study (29). 
The reward for the delayed reward was also increased from 3 to 4 sugar pellets. Krebs (2016) 
saw an increase in the choice of the delayed reward by increasing its size, as well as a larger 
effect when amphetamine was tested (30). 
The animals were not put on a restricted diet for this pilot. This is often the case in models 
that use conditioned training. Experience within the research group indicates that the learning 
is greatly sped up by restricting the diet. 
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Studies indicate that a restricted diet decrease the number of omissions but do not affect the 
choice of lever (29, 31). 
While the principle of the delay discount task is simple, that the subject is to choose between 
two rewards, there are a number of methodological questions that must be considered. What 
affects the choice of one reward (or lever) over the other? 
Evenden & Ryan (1996) identified three factors that might influence the choice of lever 
during the delay discount task, at baseline: 1) the programmed delay, 2) the habit to respond 
on one of the levers as the session progresses and 3) a conditioned association of the delay-
lever with delay (9). 
Ideally, the first factor would dominate in the rat’s choice of lever. The second and third 
factors would make the result of the task harder to interpret and if their influence of choice is 
large, one could question the use of the method as a way to measure impulsivity. 
Earlier studies suggest that the second factor play a lesser part (9, 31) which can be tested by 
using a mock delay-discount task where the delay on each block is 0 seconds.  
Several studies see a choice of the delayed lever at 0 seconds below 100% (23). This could be 
explained by the third factor identified above. 
It was also noted during this project, that some rats chose the immediate lever almost always 
and independent of delay. It can be compared to Madden (2010) that saw that some rats could 
only be made to press the delayed lever at a very short delay (around 3 seconds) and only 
after a very high number of training sessions (24). 
This problem was also identified by Evenden & Ryan (1996) and interestingly enough, they 
found that this behavior could be counteracted by assigning the rats that only chose one lever 
to a program where they could only choose the other lever (9). 
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More animals should be used in a more full scale experiment to achieve a statistical 
significant effect of delay, both in training and when comparing different treatment groups in 
experimental procedures. As can be seen in figure 4, there was a considerable variance in the 
choice of the levers, which is known to be the case from other studies (23). 
One could also consider using younger rats and potentially rats of a different breed.  
In this project, Wistar rats were used. Both Wistar rats and several other breeds have been 
used in other studies and they have been able to learn the model (24, 26). There could 
however be a difference in how fast different breeds learn and adapt in the model. The author 
of this thesis has found no such studies comparing different breeds in the delay discount task. 
While no useful result in regard to the effect of Pramipexole in this model could be found, 
there have been valuable lessons learned about the model itself. 
The research group will continue to use the model for further studies of both Pramipexole and 
other compounds, taking advantage of the changes to the protocol that was listed above. 
One future project will be to study the combination of reserpine, which is a monoamine 
depleting drug, and Pramipexole. This combination has been seen to increase impulsive 
behavior in rats (32). 
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Populärvetenskaplig sammanfattning 
Vi har alla en tendens att bete oss mer eller mindre impulsivt. Det kan handla om impulsiva 
köp på internet eller andra dålig beslut som vi senare ångrar.  
Vid vissa psykiatriska sjukdomar utgör det impulsiva beteendet ett stort problem som får 
svåra konsekvenser, som till exempel vid spelberoende och alkoholberoende. Även vissa 
läkemedel kan ge biverkningar som innebär dålig kontroll av impulser. 
Ett sådant läkemedel är Pramipexol, som är en så kallad dopaminagonist. Pramipexol används 
vid behandlingen av Parkinssons sjukdom och behandlar effektivt motoriska problem som 
uppstår vid denna sjukdom. En del patienter som tar detta läkemedel får dock problem att 
kontrollera impulser, vilket kan resultera i spelberoende eller skadligt sexuellt beteende. 
Ett annat läkemedel, OSU6162, har i en tidigare studie setts minska impulsivt beteende hos 
råttor. Det är ett läkemedel som utvecklats i Sverige men som idag inte används kliniskt. 
Det finns flera olika sätt att inom forskningen mäta impulsivt beteende. En metod är den så 
kallade delay discounting. Denna metod går ut på att försöksobjektet får välja mellan två olika 
belöningar: en liten belöning som man direkt får tillgång till och en större belöning som man 
först efter en stund får tillgång till. Om försöksobjektet väljer den mindre belöningen skulle 
detta kunna tolkas som impulsivt beteende.  
I detta projekt har råttor studerats i en delay discounting modell där de har kunnat välja 
mellan de två olika belöningarna (en mindre som kommer omedelbart och en större som 
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kommer efter en fördröjning) genom att trycka på spakar. 
Syftet har varit att studera om impulsivt beteende kan framkallas genom att behandla råttorna 
med Pramipexol och, om så är fallet, huruvida OSU6162 kan motverka detta beteende. 
Tyvärr kunde inget resultat fås från försöken då behandling med Pramipexol resulterade i att 
råttorna blev trötta och inte tryckte på spakarna. 
Trots detta har projektet gett viktiga lärdomar om hur denna modell fungerar och planen är att 
fortsätta använda den till att studera olika läkemedel. 
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